Controlled off-label use of recombinant activated factor VII (NovoSeven) can build evidence base.
D001777:Blood Coagulation / Q000187:drug effects*; D003029:Coagulants / Q000008:administration & dosage / Q000009:adverse effects; D015942:Factor VIIa / Q000008:administration & dosage / Q000009:adverse effects; D006470:Hemorrhage / Q000188:drug therapy* / Q000401:mortality; D006488:Hemostasis, Surgical / Q000706:statistics & numerical data; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D003029:Coagulants; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa